Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

EdiGene Approved to Start China Trial of Gene-Edited Stem Cell Therapy

publication date: Jan 18, 2021

EdiGene, a Beijing company, was approved to start China clinical trials of ET-01, its gene-edited stem cell therapy, to treat transfusion dependent β-thalassemia. Thalassemia is a group of blood diseases characterized by decreased or absent synthesis of normal globin chains. Patients with transfusion dependent forms of the disease require regular transfusions to live. EdiGene said the NMPA approval was the first gene-editing therapy and the first hematopoietic stem cell therapy IND application approved in China. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital